During this segment, Michelle Petri, MD, MPH, explains how systemic lupus erythematosus (SLE) burdens patients and can lead to disability under our country’s current standard of care.
Because SLE can be a life-threatening disease, as it presents in many different ways, Dr Petri concludes that the disease’s relapsing-remitting pattern can make the disease “unpredictable.”
Dr Petri explores the importance for preventive therapy and education to help improve survival. She further explains that Europe seems to be ahead of the United States in terms of treatment adherence and claims that as many as 40% of patients with lupus aren’t taking their anti-malarial therapy regularly even though the use of hydroxychloroquine can reduce flares, lupus nephritis, thrombosis, and, in 2 different studies, has been shown to improve survival.
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Risk for Second Primary Melanoma Increases After Primary Melanoma Diagnosis as Men Age
March 28th 2024A population-based cohort study out of Norway has found that older men have a higher risk of developing second primary invasive melanoma following an initial primary melanoma, suggesting the benefits of increased surveillance in these patients.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.
Read More